National Research Development Corporation

Chiron Corporation

Biocine S.p.a.

Arie J Zuckerman

Vittoria Pellegrini

Jacinta Skelly

Nicoletta Fineschi

Colin R Howard

A process is described for the purification or the hepatitis A virus, which allows one to obtain with good yields a pure product, in which organic material collected by centrifugation after lysis or the culture cells is submitted to gel filtration and successively to ion exchange chromatography.

Process for purifying hepatitis A virus (HAV), virus thus purified and

A process is described for the purification of the hepatitis A virus, which allows one to obtain with good yields a pure product, in which organic material collected by centrifugation after lysis of the culture cells is submitted to gel filtration and successively to ion exchange chromatography.

Process for purifying hepatitis a virus (HAV), and vaccine compositions

Immunogenically active fragments of hepatitis B surface antigen, which are a glycoprotein of molecular weight about 28,000 (gp 28) and a protein of molecular weight about 23,000 (p 23), obtained by known methods by treatment of surface antigen with detergent, are prepared in micelle form substantially free from detergent. The micelles are at least as immunogenic as the unfragmented antigen from which they are derived and are useful in the preparation of hepatitis B vaccine. The detergent is removed by layering the detergent containing fragmentation product on an aqueous buffer containing a sucrose gradient and centrifuging the layered buffer when micelles containing both gp 28 and p 23 form and can be recovered in substantially detergent free form from the centrifuged layered buffer.

Relating to hepatitis B vaccine

Hepatitis B vaccine

Growing community of inventors

London, United Kingdom

Arie J Zuckerman